Alain Ravaud
#142,411
Most Influential Person Now
Researcher
Alain Ravaud's AcademicInfluence.com Rankings
Alain Ravaudbiology Degrees
Biology
#10152
World Rank
#13452
Historical Rank
Cell Biology
#469
World Rank
#480
Historical Rank
Molecular Biology
#1447
World Rank
#1474
Historical Rank
Biochemistry
#1589
World Rank
#1721
Historical Rank
Download Badge
Biology
Alain Ravaud's Degrees
- PhD Biomedical Sciences University of Bordeaux
- Masters Biochemistry Université Paris Cité
Why Is Alain Ravaud Influential?
(Suggest an Edit or Addition)Alain Ravaud's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. (2015) (4550)
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma (2018) (2700)
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial (2007) (2234)
- Phase 3 trial of everolimus for metastatic renal cell carcinoma (2010) (968)
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial (2018) (961)
- Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma (1998) (909)
- Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. (2010) (784)
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (750)
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial (2019) (611)
- Sunitinib Alone or after Nephrectomy in Metastatic Renal‐Cell Carcinoma (2018) (585)
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. (2016) (558)
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. (2013) (541)
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study (2017) (495)
- Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy (2002) (473)
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. (2018) (438)
- Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. (2012) (370)
- Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. (2002) (359)
- Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. (2006) (333)
- Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. (2008) (313)
- Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. (1998) (308)
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (2019) (303)
- Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. (2000) (269)
- Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy (2004) (228)
- Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding. (1990) (210)
- Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study (2017) (205)
- Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. (2010) (203)
- Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. (2017) (200)
- Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy (2001) (199)
- Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis (2007) (197)
- Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. (2015) (190)
- IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC) (2018) (189)
- Functional decline in older patients with cancer receiving first-line chemotherapy. (2013) (186)
- Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. (2004) (177)
- Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. (1999) (167)
- Sequential sorafenib and sunitinib for renal cell carcinoma. (2009) (152)
- Immune checkpoint inhibitors and elderly people: A review. (2017) (147)
- Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. (2018) (145)
- Timing and Specificity of the Cognitive Changes Induced by Interleukin-2 and Interferon-&agr; Treatments in Cancer Patients (2001) (144)
- The official French guidelines to protect patients with cancer against SARS-CoV-2 infection (2020) (141)
- Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. (2011) (137)
- Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial (2020) (130)
- Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. (2012) (123)
- Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. (2015) (114)
- First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. (2008) (114)
- The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. (2010) (113)
- Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma (2020) (109)
- Routinely performed multiparametric magnetic resonance imaging helps to differentiate common subtypes of renal tumours (2014) (107)
- AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney (2012) (106)
- Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. (2015) (102)
- Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. (2005) (92)
- Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial (2005) (91)
- Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape. (1999) (89)
- Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). (2009) (89)
- Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. (2012) (87)
- A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma (2007) (86)
- Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. (2011) (83)
- A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS). (2018) (82)
- Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. (2008) (81)
- Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie. (1998) (81)
- Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients (2007) (79)
- Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. (2016) (79)
- BLADDER CANCER: ESMO CLINICAL PRACTICE GUIDELINE FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP†. (2021) (79)
- Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. (1999) (77)
- Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial (2008) (75)
- A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. (2017) (74)
- First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†. (2015) (72)
- A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). (2017) (71)
- RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. (2015) (70)
- Lung Tumors Treated With Percutaneous Radiofrequency Ablation: Computed Tomography Imaging Follow-Up (2011) (69)
- Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology. (2014) (67)
- Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). (2014) (66)
- Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas. (2017) (66)
- RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC)after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter Phase-III study (2008) (66)
- Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy (2016) (65)
- A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). (2011) (64)
- Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC). (2006) (64)
- Update on the medical treatment of metastatic renal cell carcinoma. (2008) (64)
- IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). (2017) (63)
- Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux. (2010) (63)
- A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. (2014) (63)
- Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. (2015) (62)
- Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. (2014) (60)
- Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. (2009) (60)
- Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. (2007) (59)
- Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma (2013) (59)
- Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. (2010) (59)
- Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie (2005) (58)
- Clinical biomarkers of response in advanced renal cell carcinoma. (2013) (56)
- Ten-year experience of percutaneous image-guided radiofrequency ablation of malignant renal tumours in high-risk patients (2013) (55)
- A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. (1998) (55)
- Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. (2020) (55)
- Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. (2012) (55)
- A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. (2012) (55)
- Lowered Serum Dipeptidyl Peptidase IV Activity is Associated with Depressive Symptoms and Cytokine Production in Cancer Patients Receiving Interleukin-2-Based Immunotherapy (2001) (54)
- Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. (2007) (53)
- Effi cacy of everolimus in advanced renal cell carcinoma : a double-blind , randomised , placebo-controlled phase III trial (2008) (52)
- Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon‐α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial (2011) (51)
- Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. (2009) (51)
- Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. (2005) (51)
- Multiparametric magnetic resonance imaging for the differentiation of low and high grade clear cell renal carcinoma (2014) (50)
- Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer (2014) (49)
- Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. (2017) (48)
- CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. (2015) (48)
- Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis (2008) (47)
- Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population. (2019) (47)
- Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. (1998) (47)
- Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials. (1992) (46)
- Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial. (2016) (46)
- Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma. (2012) (45)
- Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. (2015) (45)
- Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib (2018) (44)
- The experimental renal cell carcinoma model in the chick embryo (2012) (44)
- Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. (1994) (42)
- Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial (2019) (41)
- First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG). (2015) (41)
- An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer (2021) (41)
- Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy? (2021) (41)
- Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer. (2003) (41)
- First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP). (2012) (40)
- Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways (2008) (40)
- Optimizing the Use of Sunitinib in Metastatic Renal Cell Carcinoma: An Update From Clinical Practice (2010) (39)
- Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. (2019) (38)
- Is Multiparametric MRI Useful for Differentiating Oncocytomas From Chromophobe Renal Cell Carcinomas? (2017) (38)
- Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis (2020) (37)
- Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression. (2016) (37)
- Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial. (2021) (36)
- What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? (2013) (35)
- How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. (2009) (35)
- Optimal management of renal cell carcinoma in the elderly: a review (2013) (34)
- Laparoscopic radical prostatectomy in renal transplant recipients. (2009) (34)
- Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study. (2018) (33)
- Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort (2020) (33)
- Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial (2018) (33)
- Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study. (2017) (33)
- Experience with sunitinib in the treatment of metastatic renal cell carcinoma (2012) (32)
- Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis. (2019) (32)
- Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study (2018) (32)
- An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies (2019) (32)
- Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management (2007) (31)
- Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01). (2011) (31)
- Genitourinary tumors, non-prostate (2012) (31)
- Avelumab in patients with metastatic urothelial carcinoma: Pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial. (2017) (30)
- Targeted therapy and elderly people: A review. (2016) (30)
- UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial. (2001) (30)
- Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. (2021) (29)
- Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms (2014) (28)
- Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib (2014) (28)
- PET Scans for Decision-Making in Metastatic Renal Cell Carcinoma: A Single-Institution Evaluation (2007) (26)
- Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†. (2015) (26)
- Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial (2003) (26)
- Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. (2020) (26)
- Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFNα in Patients with Good Prognosis Metastatic Renal Cancer (2008) (25)
- Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma. (2015) (25)
- Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC). (2011) (25)
- Gastric lipase in alcoholic pancreatitis (1990) (25)
- Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy (2017) (25)
- Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up. (2018) (24)
- Combination of Gemcitabine and Doxorubicin in Rapidly Progressive Metastatic Renal Cell Carcinoma and/or Sarcomatoid Renal Cell Carcinoma (2011) (24)
- Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications. (2013) (24)
- Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort (2014) (24)
- Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers. (2013) (24)
- Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib (2007) (24)
- A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma. (1995) (24)
- Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis (2012) (24)
- Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension. (1989) (24)
- Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways. (2011) (23)
- Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial (2019) (23)
- Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study. (2016) (23)
- Efficacy and safety of first-line bevacizumab (BEV) plus interferon-{alpha}2a (IFN) in patients (pts) >=65 years with metastatic renal cell carcinoma (mRCC) (2008) (22)
- Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered. (2017) (22)
- Combination therapy in metastatic renal cell cancer. (2013) (22)
- Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC) (2007) (21)
- Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC). (2018) (21)
- Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (20)
- Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year (2012) (20)
- Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice (1999) (20)
- Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis (2018) (20)
- Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial. (2013) (20)
- VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma. (2010) (19)
- 257 UPDATED DATA FROM A PHASE 3 TRIAL OF EVEROLIMUS (RAD001) VERSUS PLACEBO IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (2009) (18)
- Is intravenous (iv) IL2 superior to subcutaneous (sc) IL2 in good prognosis patients (pts) with metastatic renal cell carcinoma (MRCC) receiving a combination of IL2 and alpha interferon (IFN)? Results of the prospective randomized PERCY Duo trial. (2006) (18)
- Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience (2019) (18)
- Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. (2014) (18)
- Exposure–response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice (2011) (18)
- Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial (2001) (18)
- Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. (2021) (17)
- Subcutaneous interleukin‐2 and interferon α in the treatment of patients with metastatic renal cell carcinoma—Less efficacy compared with intravenous interleukin‐2 and interferon α (2002) (17)
- Real‐life patterns of use, safety and effectiveness of sunitinib in first‐line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study (2017) (17)
- Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology. (2012) (17)
- A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT). (2014) (17)
- Amplification of epidermal growth factor receptor gene in renal cell carcinoma. (2010) (17)
- Taxane-induced glaucoma (1999) (17)
- Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives. (2021) (17)
- Les thérapeutiques ciblées du cancer de vessie localement avancé et/ou métastatique (2008) (16)
- Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. (2012) (16)
- Bladder cancer in patients after organ transplantation (2010) (16)
- Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment (2019) (16)
- Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients. (2017) (16)
- Gastric lipase in alcoholic pancreatitis. Comparison of secretive profiles following pentagastrin stimulation in normal adults and patients with pancreatic insufficiency. (1990) (16)
- [Cabozantinib: Mechanism of action, efficacy and indications]. (2017) (16)
- Are we ready for day-case partial nephrectomy? (2016) (15)
- Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial (2020) (15)
- Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie. (2002) (15)
- Emerging antiangiogenics for renal cancer (2013) (15)
- Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. (2022) (15)
- Present achievements in the medical treatment of metastatic renal cell carcinoma. (1999) (15)
- First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC). (2010) (14)
- Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort. (2016) (14)
- Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment. (2017) (14)
- Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study. (2020) (14)
- Current management and future perspectives of penile cancer: An updated review. (2020) (14)
- A survey in general practice about undergraduate cancer education: results from Gironde (France). (1991) (14)
- High-dose interleukin-2 two days a week for metastatic renal cell carcinoma: a FNCLCC multicenter study. (1994) (14)
- Long-term prognosis of septic shock in cancer patients (2020) (14)
- Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial (2018) (14)
- A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC) previously treated with antiangiogenic therapy. (2013) (13)
- Infection à SARS-CoV-2/COVID 19 et cancers solides : synthèse des recommandations à l’attention des professionnels de santé (2020) (13)
- Protein kinase inhibitors in renal cell carcinoma (2014) (13)
- How to report toxicity associated with targeted therapies? (2016) (13)
- Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma (2021) (13)
- Phase II study of Interferon-α and all-trans retinoic acid in metastatic renal cell carcinoma (1998) (13)
- Adjuvant bacillus Calmette-Guérin therapy in non-Hodgkin's malignant lymphomas: long-term results of a randomized trial in a single institution. (1990) (13)
- Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy. (2018) (13)
- [SARS-CoV-2/COVID 19 Infection and Solid Cancers: Synthesis of Recommendations for Health Professionals]. (2020) (13)
- Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response (2017) (12)
- A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS). (2018) (12)
- Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study. (2012) (12)
- [Does surgery promote the development of metastasis in melanoma?]. (2000) (12)
- in vitro immunization of patient T cells with autologous bone marrow antigen presenting cells pulsed with tumor lysates (2000) (12)
- 856PAvelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN solid Tumor study: updated analysis with ≥6 months of follow-up in all patients (2017) (12)
- Randomized phase II study of first-line everolimus plus bevacizumab (E+B) versus interferon α-2a plus bevacizumab (I+B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results. (2013) (11)
- Interferon alpha for the treatment of advanced renal cancer (2005) (11)
- Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. (2012) (11)
- Treatment of spinal metastases in renal cell carcinoma: A critical review. (2018) (11)
- Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma (2018) (11)
- Cancer chemotherapy in the elderly: a series of 51 patients aged>70 years (2004) (11)
- Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment (2020) (11)
- Effets secondaires de l'interleukine 2. (1991) (11)
- Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. (2021) (11)
- Patient‐reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma (2020) (11)
- Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemia (2007) (11)
- [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma]. (2010) (10)
- M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: Results from a phase I cohort. (2018) (10)
- Management of Immune Checkpoint Inhibitor Toxicities (2020) (10)
- Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group. (1999) (10)
- Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis (2020) (10)
- Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports. (2009) (10)
- The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies (2013) (10)
- [Targeted therapy for locally advanced and/or metastatic bladder cancer]. (2008) (10)
- Colonic Metastasis of a Renal Carcinoma. A Case Report (1992) (10)
- Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials (2016) (10)
- Everolimus in metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients (pts) with one versus two prior vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) therapies enrolled in the phase III RECORD-1 study. (2011) (9)
- In vitro production of human antigen presenting cells issued from bone marrow of patients with cancer. (1997) (9)
- CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial. (2018) (9)
- Phase II randomized trial of docetaxel plus estramustine (DE) versus docetaxel (D) in patients (pts) with hormone-refractory prostate cancer (HRPC): a final report. (2004) (9)
- Checkpoint inhibitors in metastatic papillary renal cell carcinoma. (2021) (9)
- O14 Screening of elderly patient with cancer for early death risk. Results of a prospective multicentric study of 364 patients under chemotherapy (2006) (9)
- Chimiothérapie d'induction et traitement combiné conservateur des sarcomes des tissus mous de l'adulte. (1992) (9)
- Early D epressive S ymptoms i n C ancer P atients R eceiving Interleukin 2 a nd/or I nterferon A lfa-2b T herapy (2000) (8)
- Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). (2010) (8)
- Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT). (2014) (8)
- How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study. (2014) (8)
- Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: Results of the ETNA cohort study. (2010) (8)
- First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies? (2021) (8)
- The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours (2021) (8)
- Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. (2021) (8)
- UFT and oral calcium folinate as first-line chemotherapy for metastatic gastric cancer. (1999) (7)
- Phase I and pharmacokinetic (PK) dose-adjusted study of IV vinflunine (VFL) in cancer patients with liver dysfunction (LD): Pharmacokinetic results (2007) (7)
- Adjuvant Sunitinib in Renal-Cell Carcinoma. (2017) (7)
- Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors (2011) (7)
- 4518 POSTER First-line bevacizumab improves progression-free survival with lower doses of interferon-a2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN) (2007) (7)
- Combined radiofrequency ablation and antiangiogenic drug for the treatment of recurrent renal tumor. (2009) (7)
- Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the Literature. (2019) (7)
- Inhibiteurs de mTOR : temsirolimus et évérolimus dans le traitement du cancer du rein (2010) (7)
- 4008 POSTER Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN) (2007) (6)
- Vinorelbine/5-FU combination in metastatic breast cancer chemotherapy. A retrospective study of 63 cases. (1996) (6)
- Current Perspectives in Metastatic Renal Cell Carcinoma Treatment: The Role of Mammalian Target of Rapamycin (mTOR) Inhibition (2009) (6)
- A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France (2017) (6)
- PDL-1 and PDL1 expressions in clear cell renal cell carcinoma (ccRCC) of metastatic patients with sunitinib first-line treatment. (2015) (6)
- TiNivo: Tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC): Final results (2019) (6)
- Meta-analysis of stomatitis incidence in everolimus (EVE) clinical studies and its relationship with efficacy. (2014) (6)
- [Cell therapy in solid tumors]. (2001) (6)
- Phase II trial of sunitinib in renal cell cancer with untreated brain metastases. (2011) (6)
- Influence of age on the pharmacokinetics of i.v. vinflunine: Results of a phase I trial in elderly cancer patients (2012) (6)
- Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer. (2010) (6)
- Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression (2021) (6)
- Multicenter Randomized Phase 2 Trial of Gemcitabine – Platinum with or without Trastuzumab (T) in Advanced / Metastatic Urothelial Carcinoma (A/MUC) with HER2 Overexpression (2012) (6)
- New challenges in kidney cancer therapy: bevacizumab. (2007) (6)
- Clinical benefits of non‐taxane chemotherapies in unselected patients with symptomatic metastatic castration‐resistant prostate cancer after docetaxel: the GETUG‐P02 study (2015) (5)
- Everolimus with bevacizumab versus interferon alfa-2a plus bevacizumab as first-line therapy in patients with metastatic clear cell renal cell carcinoma. (2010) (5)
- Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction (2013) (5)
- Avelumab treatment for metastatic urothelial carcinoma in the phase Ib JAVELIN Solid Tumor Study: Updated safety and efficacy analysis with ≥ two years of follow-up. (2019) (5)
- Effectiveness and safety in very elderly patients treated by bevacizumab (BV) plus chemotherapy in first-line therapy of metastatic colorectal cancer: Results of ETNA, a French cohort study. (2011) (5)
- Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next? (2019) (5)
- Epithelial growth factor receptor (EGFR) pathway and renal cell carcinoma (2007) (5)
- Chimiothérapie systémique des adénocarcinomes colorectaux métastatiques (1992) (5)
- 247 A phase III trial of recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) as corrective treatment in patients (PTS) with neutropenic fever following antineoplastic chemotherapy (CT): Results of an intermediate analysis (1995) (5)
- ADJUVANT THERAPY BY BCG OF NON‐HODGKIN'S MALIGNANT LYMPHOMAS IN A CONTROLLED TRIAL: AN UPDATE (1989) (5)
- Estimand framework: Are we asking the right questions? A case study in the solid tumor setting (2020) (5)
- Comment on: Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma (2008) (4)
- [Update on renal cell carcinoma]. (2002) (4)
- 199O A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis (2020) (4)
- Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature (2014) (4)
- Syndromes paranéoplasiques à expression rénale et atteintes rénales des cancers (2012) (4)
- Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort (2016) (4)
- A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment (2020) (4)
- 2630 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic urothelial carcinoma: A phase Ib trial (2015) (4)
- Current and Future Treatment Options for Metastatic Renal Cell Carcinoma (2009) (4)
- [Relay chemotherapy using continuous perfusion of cisplatin and fluoro-uracil in advanced cancer of the breast. Analysis of a series of 50 cases]. (1990) (4)
- 7126 What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? – Experience from AVOREN (2009) (4)
- VOTRAGE study: Phase I dose-escalation study of pazopanib in unfit older patients. (2021) (4)
- New Insights into Adjuvant Therapy in Renal Cell Carcinoma: Is the Chapter of VEGF Inhibitors Definitely Closed? (2021) (4)
- Phase II study of interferon-alpha and all-trans retinoic acid in metastatic renal cell carcinoma. (1998) (4)
- Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial. (2018) (4)
- Case Report 2. Severe erythema multiforme induced by two consecutive anti-angiogenic drugs (2007) (4)
- [The mechanism of tumor angiogenesis]. (2007) (4)
- Phase III, randomized, placebo-controlled study of everolimus in patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients intolerant of prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. (2011) (4)
- Are immune checkpoint inhibitors (ICI) a valid option for papillary renal cell carcinoma (pRCC)? A multicenter retrospective study. (2019) (4)
- Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours (2013) (4)
- LBA39IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) (2017) (4)
- Lapatinib and renal cell carcinoma (2012) (4)
- First-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial. (2018) (3)
- Place de la chimiothérapie adjuvante dans le traitement des sarcomesdes tissus mous de l’adulte (1997) (3)
- Nouveautés anatomopathologiques et évolution des thérapeutiques actuelles dans les cancers du rein (2006) (3)
- Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials (2017) (3)
- Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors (2020) (3)
- Dramatic response after anti PD1 treatment failure in a squamous cell carcinoma of the maxillary sinus. (2018) (3)
- Key considerations in patient selection for the use of targeted therapy in metastatic renal cell carcinoma (2007) (3)
- Comparison of two major prognostic models for patients with metastatic renal cell carcinoma treated in the contemporary era of targeted therapies. (2011) (3)
- Symptomatic Neurological Epidural Metastasis with Interleukin-2 Therapy in Metastatic Renal Cell Carcinoma (2002) (3)
- Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): A long-term overall survival (OS) and safety update from the phase III IMvigor211 study (2019) (3)
- Contrast-enhanced U.S.-guided biopsies following MRI in men with elevated PSA and previous negative biopsy. (2011) (3)
- Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma. A Systematic Review and Network Meta-Analysis. (2020) (3)
- Investigation of Total and Conjugated Bilirubin Determination during the Neonatal Period (1993) (3)
- An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives (2022) (3)
- Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: A retrospective study (2022) (3)
- [Anti-angiogenic treatment in the management of metastatic renal cell carcinoma]. (2008) (3)
- Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve. (2020) (3)
- genitourinary tumours, non prostatePhase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC) (2016) (3)
- 7123 First-line bevacizumab + reduced-dose interferon-alpha2a in patients (pts) with metastatic renal cell carcinoma (mRCC): an update on overall survival (2009) (3)
- Les traitements anti-angiogéniques dans la prise en charge du cancer du rein métastatique (2008) (3)
- [Neoadjuvant chemotherapy and combined conservative treatment of soft tissue sarcoma in the adult]. (1992) (3)
- Neutrophil-to-lymphocyte ratio as a potential prognostic factor of disease-free survival in high-risk renal cell carcinoma: Analysis of the S-TRAC trial. (2018) (3)
- La fréquence des formes indolores de pancréatite chronique est-elle sous-estimée? (1989) (3)
- [Radiofrequency ablation in the treatment of liver and lung tumors]. (2009) (3)
- Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first‐line metastatic renal carcinoma (SUNRISES study) (2020) (3)
- [Adverse effects of interleukin 2]. (1991) (3)
- A Step Ahead in Metastatic Renal Cell Carcinoma. (2021) (3)
- Sorafenib dose escalation in treatment‐naïve patients with metastatic renal cell carcinoma: a non‐randomised, open‐label, Phase 2b study (2017) (3)
- Révision de l’index thérapeutique des thérapies ciblées dans le cancer du rein : le mieux peut-il être l’ennemi du bien ? La toxicité peut-elle prédire l’efficacité ? (2014) (3)
- [Revision of therapeutic index for targeted treatment in kidney cancer: What if toxicity could predict efficacy?]. (2014) (3)
- [Hand-foot syndrome and sorafenib]. (2009) (3)
- Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature (2017) (2)
- The interest of sequential treatment with immune check point inhibitors followed chemotherapy: A case report. (2019) (2)
- Current options for the treatment of locally advanced and metastatic renal cell carcinoma : focus on sunitinib (2007) (2)
- Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC). (2019) (2)
- Evaluation of medical students' hospital training: interest of students' essays. (1992) (2)
- Patient-reported outcomes in a randomized trial of everolimus with metastatic renal cell carcinoma patients. (2009) (2)
- Thérapie cellulaire et cancer du rein (2003) (2)
- Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study. (2017) (2)
- 862PTreatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective (2017) (2)
- Analysis of characteristics in patients (pts) with metastatic renal cell cancer (MRCC) who achieved a prolonged benefit from sunitinib or sorafenib (2008) (2)
- Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Comprehensive tumour genomic and transcriptomic analyses (2019) (2)
- Quelle pratique de la néphrectomie partielle en France (2008) (2)
- Prognostic factors for cancer patient admitted to a medical intensive care unit (2020) (2)
- [Role of adjuvant chemotherapy in the treatment of soft tissue sarcoma]. (1997) (2)
- CGH array and matching gene expression profiling for identification of distinct molecular variants among type II papillary renal cell carcinomas. (2014) (2)
- Editorial Comment to Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma (2012) (2)
- TiNivo - tivozanib combined with nivolumab: Safety and efficacy in patients with metastatic renal cell carcinoma (mRCC). (2018) (2)
- 7121 Bevacizumab (BEV) and interferon (IFN) therapy does not increase risk of cardiac events in metastatic renal cell carcinoma (mRCC) (2009) (2)
- Metronomic chemotherapy for renal cancer in the landscape of targeted therapy. (2010) (2)
- [What is the clinical practice of partial nephrectomy in France?]. (2008) (2)
- Soluble CD 146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma (2018) (2)
- Breastfeeding and breast cancer risk by receptor status — a systematic review andmeta-analysis (2015) (2)
- Targeted therapy in metastatic renal cell carcinoma: efficacy, adverse-event management and key considerations (2007) (2)
- Perception du cancer chez les médecins généralistes. Evolution sur 15 ans (1993) (2)
- Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First‐Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study (2019) (2)
- 433 Decrease of pro-angiogenic monocytes predicts clinical response to anti-angiogenic treatment in patients with metastatic renal cell carcinoma (mRCC) (2015) (2)
- Molecular Pathways in Metastatic Renal Cell Carcinoma: The Evolving Role of Mammalian Target of Rapamycin Inhibitors (2009) (2)
- Cancer chemotherapy in the elderly: a series of 51 patients aged greater than 70 years. (1991) (2)
- Patupilone combined with carboplatin in patients (pts) with advanced solid tumors: preliminary safety and activity results (2008) (2)
- SUNITINIB TREATMENT OF RENAL ADJUVANT CANCER (S-TRAC): A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF SUNITINIB VS. PLACEBO IN SUBJECTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) (2012) (2)
- Actualités sur le cancer du rein (2002) (2)
- Exploring Biological Predictive Factors of Progression After Surgery in High-Risk Renal Cell Carcinoma: Results From the French Cohort of the Randomized S-TRAC Trial Patients (2020) (2)
- Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression. (2019) (2)
- Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting (2020) (2)
- Systemic therapy of renal cell carcinoma (2014) (2)
- Effectiveness and safety of bevacizumab plus FOLFIRI in first-line metastatic colorectal cancer (mCRC) after 24 months of follow-up for the ETNA cohort study. (2010) (2)
- Which place for avelumab in the management of urothelial carcinoma? (2019) (2)
- [Renal involvement in cancer and renal paraneoplastic syndromes]. (2012) (2)
- Treatment of metastatic melanoma with subcutaneous interleukin 2 interferon alpha 2 a and dacarbazine: 190 (1993) (2)
- 719 EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SUBGROUP ANALYSIS OF PATIENTS WITH A REDUCTION IN TUMOR BURDEN ENROLLED IN A RANDOMIZED, PLACEBO-CONTROLLED, PHASE II TRIAL (2011) (2)
- VOTRAGE study pazopanib in a population of "frail" elderly patients after geriatric assessment: A phase I study with geriatric criteria. (2018) (2)
- EGF receptor inhibitors (2011) (1)
- Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN). (2021) (1)
- Current Strategy in the Treatment of Metastatic Renal Cell Carcinoma (2005) (1)
- [Systemic chemotherapy in metastatic colorectal adenocarcinomas]. (1992) (1)
- [Perception of cancer by general practitioners. Development over 15 years]. (1993) (1)
- m-TOR inhibitor as potential radiosensitizer for head and neck squamous cell carcinoma: A case report of an organ transplant patient and review of the literature. (2016) (1)
- Pulmonary aspergilloma: an unexpected complication of radiofrequency ablation in the management of targeted therapy for a patient with metastatic renal cell carcinoma. (2014) (1)
- VOTRAGE study pazopanib in vulnerable elderly patients after geriatric assessment—A phase I study with geriatric criteria. (2015) (1)
- Treatment Strategies in Metastatic Renal Cell Carcinoma (2010) (1)
- Adjuvant therapy for high‐risk renal cell carcinoma after nephrectomy how many trials are positive? Only one or more than one (2020) (1)
- [Is the incidence of painless chronic pancreatitis underestimated?]. (1989) (1)
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (1)
- [Management of muscle invasive bladder in elderly]. (2010) (1)
- Adaptation of multidisciplinary meeting decisions in a medical oncology department during the COVID epidemic in a less affected region of France: a prospective analysis from Bordeaux University Hospital (2020) (1)
- Efficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): Results of a GETUG multicenter phase II trial (Axipap). (2018) (1)
- Impact of metastatic local treatment in the strategy of metastatic renal cell carinoma including sterotactic radiotherapy, surgery, and radiofrequency in an expert center. (2018) (1)
- [Cell therapy in renal cell carcinoma]. (2003) (1)
- Analysis of the relationship between Karnofsky performance status (KPS) and tumor response in the RECORD-1 phase III trial of everolimus in patients with advanced renal cell carcinoma (RCC). (2011) (1)
- Influence of renal dysfunction on the pharmacokinetic of intravenous vinflunine: Results of a phase I trial in patients with cancer. (2011) (1)
- Outcomes and toxicities in sarcopenic patients with metastatic solid tumors treated with check point inhibitors. (2019) (1)
- Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (2020) (1)
- Prognostic factors of the loss of autonomy (LoA) in older patients with cancer receiving first-line chemotherapy. (2012) (1)
- 7114 POSTER DISCUSSION Appropriateness of Treatment Options for the Management of Patients With Advanced Renal Cell Carcinoma (RCC) Using the Validated Semi Quantitative RAND Corporation/University of California, Los Angeles (RAND/UCLA) Methodology (2011) (1)
- Sorafénib et syndrome main-pied (2009) (1)
- [New entities in pathological classification and new therapeutic options in renal cell carcinoma]. (2006) (1)
- Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature. (2016) (1)
- Principes, modalités et indication de l’administration du Radium dans les cancers, focus sur le cancer de la prostate métastatique : état des lieux (2017) (1)
- Safety of sunitinib in patients with renal cell carcinoma following nephrectomy (2020) (1)
- [Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts]. (2017) (1)
- [The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies]. (2008) (1)
- Asymptomatic stroke is an underestimated side effect of cabozantinib. (2019) (1)
- [Symptomatic treatment of pain in cervico-facial cancers]. (1992) (1)
- Stomatitis incidence and its relationship with efficacy: A meta-analysis of everolimus clinical studies. (2014) (1)
- Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy. (2021) (1)
- Cardiomyopathy after acute myocardial infarction after therapy with interleukin-2 and tumour infiltrating lymphocytes. (1992) (1)
- Development of an evidence-based reference framework for care coordination with a focus on the micro level of integrated care: A mixed method design study combining scoping review of reviews and nominal group technique. (2022) (1)
- Adjuvant therapy after nephrectomy for renal cell carcinoma (2018) (1)
- Interest of CHOI and modified CHOI criterion for evaluation of metastatic renal cell carcinomas (mRCC) patients treated with Everolimus (2011) (1)
- Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial (2022) (1)
- [Study of bioavailability parameters of propranolol in cirrhotic patients after oral administration of the delayed-action form]. (1987) (1)
- Nouvelles molécules dans le cancer de la vessie (2010) (1)
- Intérêt du métoclopramide à forte dose dans la prévention des nausées et des vomissements induits par la chimiothérapie (1990) (1)
- Intérêt des anti-angiogéniques dans le cancer du rein localement avancé et métastatique en situation néo-adjuvante : à propos de 2 cas (2008) (1)
- Peut‐on améliorer la description des séjours de chimiothérapie dans le cadre du PMSI ? Étude des facteurs prédictifs des coûts de la chimiothérapie (2003) (1)
- Oncopharmaco-épidémiologie : à propos de 10 ans d’expérience d’une plate-forme de recherche française (2016) (1)
- Gestion des effets secondaires des thérapies ciblées dans le cancer du rein : effets secondaires iatrogéniques (2011) (1)
- Association d'étoposide et d'elliptinium dans le traitement palliatif des cancers avancés du sein: analyse d'une série de soixante-huit cas (1990) (1)
- L’imagerie d’évaluation thérapeutique en pratique clinique d’oncologie urologique (2014) (1)
- ETNA : étude de terrain sur les traitements innovants en cancérologie : un antiangiogénique l’Avastin ® : données sur l’utilisation du bévacizumab en vie réelle (2009) (1)
- Tumeur infiltrant le muscle chez le patient octogénaire : quelles solutions thérapeutiques proposées ? (2010) (1)
- Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma (2009) (1)
- Comparative E ffi cacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis (2020) (0)
- [Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?]. (2014) (0)
- MP61-16 PROGNOSTIC IMPACT OF PREOPERATIVE AND POSTOPERATIVE NEUTROPHIL/LYMPHOCYTE RATIOS IN NON-METASTATIC KIDNEY CANCER (UROCCR N°61) (2021) (0)
- [Refining the French system of cost assessment for oncology patients following chemotherapy]. (2003) (0)
- 308 Phase I of axitinib and everolimus in metastatic solid tumors and extension to metastatic renal cell carcinoma (mrcc): Results of EVAX study (2015) (0)
- Robot-assisted retroperitoneal lymph node dissection and vena cava thrombectomy for residual masses of germ cell tumor (2023) (0)
- PAZOTHYR: A randomized, multicenter, open-label, phase II study of the optimal scheme of pazopanib in radioactive iodine-refractory differentiated thyroid carcinoma (RAIR-DTC). (2014) (0)
- 256 NEPHRECTOMY IMPROVES OVERALL SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA IN CASES OF FAVOURABLE MSKCC OR ECOG PROGNOSTIC FEATURES (2011) (0)
- Impact of 18FDG-PET CT in the management of invasive bladder cancer. (2020) (0)
- H y p e rkalaemia in a Thai man (1999) (0)
- Métastasectomie surrénalienne bilatérale robot-assistée pour Résection complète d’un cancer du rein métastatique (2018) (0)
- Sunitinib tolerance following an initial exposure period: Results of longitudinal PRO data from S-TRAC study. (2018) (0)
- 604 PREDICTIVE FACTORS OF IMPAIRED FROZEN KIDNEY TISSUE SAMPLES QUALITY IN THE SETTING OF ROUTINE SURGICAL ACTIVITY (2013) (0)
- ADJUVANT SUNITINIB IN PATIENTS WITH HIGH RISK RENAL CELL CARCINOMA: SUBGROUP ANALYSES FROM S‐TRAC TRIAL: PD04‐02 (2017) (0)
- Adjuvant sunitinib (SU) in patients (pts) with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial (2017) (0)
- 470 Original regimen of subcutaneous interleukin 2 (IL2) and interferon alpha (IFN) in patients with metastatic renal cell carcinoma (MRCC) ineligible to receive intravenous (I.V.) IL2 (1995) (0)
- [Gallbladder collapse in drug-induced hepatitis]. (1986) (0)
- R143: Présentation d’un modèle de base de données multidisciplinaire en réseau sur le cancer du rein (2010) (0)
- [Prostate carcinoma in the elderly]. (2008) (0)
- 97 EVEROLIMUS (EVE) IN RECORD-1 ELDERLY PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) AND MANAGEMENT OF RELATED ADVERSE EVENTS (AES) (2010) (0)
- Pulmonary arterial hypertension due to an intratumoral shunt: an unexpected side effect of sunitinib. (2017) (0)
- Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC) (2019) (0)
- Création d’une unité de coordination de la prise en charge des tumeurs rares du rein de l’adulte (2008) (0)
- Suivi evolutif par tomodensitometrie de tumeurs pulmonaires traitees par radio-frequence (2005) (0)
- Thank you Reviewers 2022 (2022) (0)
- Cancer du rein : le bout du tunnel ? (2006) (0)
- 867 Superficial soft tissue sarcomas of the adults (1995) (0)
- 1765 NEPHRECTOMY IMPROVES OVERALL SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA IN CASES OF FAVOURABLE MSKCC OR ECOG PROGNOSTIC FEATURES (2011) (0)
- Thérapie cellulaire dans les tumeurs solides (2001) (0)
- 2859 A multicenter phase II of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullar thyroid carcinoma: Mature data of THYSU study (2015) (0)
- 6070 Pattern of bevacizumab use in 1st-line therapy metastatic colorectal cancer (mCRC) in real-life practice: results of the ETNA cohort study (2009) (0)
- 418 NEW PROGNOSTIC STRATIFICATION SYSTEM IN LOCALLY ADVANCED RENAL CELL CARCINOMA PATIENTS WHO ARE CANDIDATES FOR ADJUVANT TREATMENT (2010) (0)
- Cancer Metastasis: Metastatic Renal Cell Carcinoma (2011) (0)
- A novel mechanism of HIF2-dependent PLK1-mediated metastasis and drug resistance of clear cell Renal Cell Carcinoma (2020) (0)
- Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment. (2017) (0)
- Dramatic response under combination of immune-oncology in head & neck cancer included in the Condor study: A case report. (2019) (0)
- 735 LEVEL OF EXPRESSION AND PROGNOSTIC VALUE OF CXCL4, CXCL4L1 AND CXCR3B IN CLEAR CELL RENAL CELL CARCINOMA (2011) (0)
- [Cancer of the prostate: recent findings and the immediate future]. (2007) (0)
- Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade (2022) (0)
- P6 In vitro immunization of peripheral autologous T cells by tumour extracts processed by autologous macrophages or autologous dendritic cells issued from bone marrow (1999) (0)
- Bladder Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma (0)
- Toxicity Management of Renal Cell Cancer Patients on Targeted Therapies (2012) (0)
- OP0336 COMMONLY USED DRUGS IN RHEUMATOLOGY MAY ALTER ANTI-TUMORAL RESPONSE TO IMMUNE CHECKPOINT INHIBITORS (2019) (0)
- Évolution des métastases osseuses chez les patients traités par inhibiteurs de checkpoint immunitaire (2021) (0)
- Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer? (2012) (0)
- Toux rénale : cas clinique & revue de la littérature (2010) (0)
- CHICKEN EMBRYO CHORIO-ALLANTOÏC MEMBRANE (CAM) AS AN IN VIVO RENAL CELL CARCINOMA ANGIOGENESIS MODEL (2009) (0)
- Final results of the multicenter, open-label, randomized phase II trial PAZOTHYR evaluating continuous versus intermittent administration of pazopanib in radio-iodine-refractory thyroid cancers (NCT01813136). (2020) (0)
- Toxicity and feasibility of adjuvant high dose interferon alpha-2b in patients with melanoma (1998) (0)
- 4533 POSTER Combination of gemcitabine and doxorubicin in sarcomatoid and/or rapidly progressive metastatic renal cell carcinoma (MRCC) (2007) (0)
- [Renal cell carcinoma: the end of a tunnel?]. (2006) (0)
- Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (2020) (0)
- Prognostic factors for critically ill patients with solid cancer tumours admitted to a medical intensive care unit. (2018) (0)
- GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN ESTABLISHED FEBRILE NEUTROPENIA. AUTHORS' REPLY (1999) (0)
- Traitement focal et traitement systémique dans la prise en charge du cancer du rein métastatique : une question de complémentarité (2018) (0)
- Atezolizumab for the treatment of renal cell carcinoma (2020) (0)
- Disease-free survival in patients at highest risk of recurrent renal cell carcinoma in S-TRAC. (2018) (0)
- 1757P Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) (2022) (0)
- Phase II study of axitinib for downstaging cT2a to cT1 renal tumors for allowing partial nephrectomy (AXIPAN) (2017) (0)
- Evaluation of 18FDG PET/CT in bladder cancer staging (2009) (0)
- [Quantitative imaging in uro-oncology]. (2014) (0)
- Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma (2021) (0)
- Impact of the 18F- PET/CT scan in the management of patients with high-risk or intermediate-risk prostate cancer at initial diagnosis or at recurrence. (2015) (0)
- Phase II study of axitinib for downstaging cT2a to cT1 renal tumors for allowing partial nephrectomy (AXIPAN). (2016) (0)
- Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression (2021) (0)
- 7016 POSTER Second Line Chemotherapy After Docetaxel Among Symptomatic Castration-Resistant Prostate Cancer (CPRC) Patients – GETUG-P02 Randomized Phase II Trial (2011) (0)
- Taxane-induced glaucoma (2000) (0)
- La recherche clinique au sein du cancéropôle Grand Sud-Ouest (2006) (0)
- Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response (2017) (0)
- Cancer de la vessie. Editorial. (2010) (0)
- Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? Transcriptomic characterization of the immune infiltrate (2019) (0)
- 1776 E-CADHERIN, N-CADHERIN AND TWIST EXPRESSION IN HIGH RISK BLADDER CANCER (2012) (0)
- Interleukin-2 with interferon- α 2a and 5-fluorouracil improves objective response rate compared with tamoxifen in people with metastatic renal cell carcinoma (2002) (0)
- Abstract 1771: Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory molecular analysis of tumor biomarkers (2017) (0)
- EE301 Cost-Effectiveness Analysis of Avelumab Plus Best Supportive Care (BSC) As First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma (La/mUC) in France (2022) (0)
- A multi-layered systems approach for renal cell carcinoma (2020) (0)
- [Bladder cancer. Editorial]. (2010) (0)
- Feasibility of robotic-assisted partial nephrectomy for complete remission of metastatic renal cell carcinoma after long exposure to immune checkpoint inhibitors (UroCCR-106) (2022) (0)
- [Not value to the systematic study of different tumor markers for disclosing bone metastasis]. (1989) (0)
- Prognostic factors in critically ill patients with solid cancer admitted to medical intensive care unit. (2018) (0)
- Repeated tumor infiltrating lymphocytes (TIL) infusion in metastatic malignant melanoma (MMM) (1993) (0)
- Thromboembolic (TE) complications in germ cell tumor (GCT) patients: Should use of peripherally inserted central catheters (PICC-Line) be pursued? (2018) (0)
- Correlation of MET complete status and outcome in patients with metastatic clear cell renal cell carcinoma (m-ccRCC) treated by sunitinib. (2016) (0)
- 851PPROSPECTIVE OBSERVATIONAL STUDY ON THE EVALUATION OF EVEROLIMUS ADVERSE EVENTS (AES) IN METASTATIC RENAL CELL CARCINOMA (MRCC) AFTER FIRST-LINE ANTI-VEGF THERAPY. THE FRENCH AFINITE STUDY. (2014) (0)
- Phase I—II with repeated tumor infiltrating lymphocytes (TIL) infusion, without or with interleukin-2 (IL-2) in metastatic malignant melanoma (MMM): 292 (1993) (0)
- Traitement symptomatique des douleurs des cancers cervico-faciaux (1992) (0)
- Supplementary Material for: Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials (2017) (0)
- Vertebral metastases of cancers of unknown primary origin (2002) (0)
- [Rationale for the local treatment of metastases]. (2011) (0)
- [Not Available]. (2014) (0)
- La chimiothérapie première en cancérologie (1989) (0)
- Le Temps Accompagnement Soignant " TAS " : entre influence des contextes de mise en place au sein des services hospitaliers sur la prise en charge du patient et questionnements professionnels (2012) (0)
- Bévacizumab et temsirolimus: quel apport dans la stratégie de prise en charge du cancer du rein métastatique ? (2008) (0)
- P11 Toxicity and feasibility of adjuvant high dose interferon apha-2B in patients with melanoma in clinical oncologic practice (1999) (0)
- Quitter enfin des mauvais résultats de la chimiothérapie dans le cancer du pancréas métastatique grâce à un groupe coopératif français (2012) (0)
- Stratégie chirurgicale dans les stades localement avancés et métastatiques (2009) (0)
- Curage rétropéritonéal robot-assisté (CRP-R) pour masses résiduelles après chimiothérapie pour tumeur germinale du testicule : quels résultats chez quels patients ? (2020) (0)
- Intérêt de l'irradiation externe dans le traitement des tumeurs carcinoïdes (1989) (0)
- Quelle place pour les traitements médicaux avant et après chirurgie es stades localisés ? (2018) (0)
- Curage lombo-aortique bilatéral monobloc avec néphrectomie élargie gauche par voie laparoscopique robot-assistée (2021) (0)
- R78: Niveau d’expression et valeur pronostique de CXCL4, CXCL4L1 et CXCR3B dans le carcinome à cellules rénales claires (2010) (0)
- La tomographie par émission de positons couplée à la tomodensitométrie (TEP–TDM) au 18F-fluoro-désoxy-glucose ([18F]-FDG), avec dilution vésicale dans l’imagerie des tumeurs urothéliales. À propos de quatre cas (2009) (0)
- 211 LEVEL OF EXPRESSION AND PROGNOSTIC VALUE OF CXCL4, CXCL4L1 AND CXCR3B IN CLEAR CELL RENAL CELL CARCINOMA (2010) (0)
- Étude des effets dépressogènes des immunothérapies chez des patients atteints de cancers du rein métastatiques (2005) (0)
- Vertebral metastases of renal cancers (2002) (0)
- Hiérarchie des traitements à domicile (1989) (0)
- Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC). (2023) (0)
- Immunothérapie cellulaire du mélanome (2000) (0)
- Métastases vertébrales des cancers du rein (2007) (0)
- Adénocarcinomes à localisation primitive occulte: à propos d'une série de soixante-dix-huit cas (1986) (0)
- Enfin de la survie dans le mélanome ! Enfin une immunothérapie efficace ! (2010) (0)
- Métastases vertébrales des cancers sans primitif connu (2007) (0)
- Néphrectomie partielle laparoscopique robot-assistée après traitement néoadjuvant (2014) (0)
- Étude par analyse chromosomique sur puces à ADN d’une série de 45 cancers du rein à cellule claires métastatiques : caractérisation des profils génomiques prédictifs de la réponse ou de la résistance à un traitement antiangiogénique (sunitinib) (2016) (0)
- Coût global de prise en charge des patients atteints de cancer du rein métastatique (CAPRI) (2012) (0)
- Cancer de la prostate : les acquis récents et le futur presque immédiat (2007) (0)
- De la biologie aux thérapies moléculaires ciblées : le cancer du rein (2010) (0)
- PHASE II STUDY OF AXITINIB FOR DOWNSTAGING CT2A TO CT1 RENAL TUMORS FOR ALLOWING PARTIAL NEPHRECTOMY (AXIPAN): MP72‐19 (2017) (0)
- A propos d'un cas d'adénocarcinome rénal révélé par des métastases mammaires et laryngées synchrones (1997) (0)
- Modèle in vitro d'immunisation active antitumorale humaine par des cellules de présentation (1998) (0)
- Le cancer de la prostate du sujet âgé (2008) (0)
- Néphrectomie partielle robot-assistée après immunothérapie : faisabilité et partage d’expérience (2020) (0)
- Pourquoi un traitement local des métastases (2011) (0)
- Introduction de la deuxième édition (2007) (0)
- Nouveautés dans la prise en charge du cancer du rein. Stratégie thérapeutique en 2003 (2004) (0)
- Nomogramme prédictif de réponse ou de résistance dans les carcinomes à cellules claires du rein métastatiques traités par sunitinib en première ligne (2016) (0)
- Les traitements symptomatiques des douleurs des métastases osseuses vertébrales (1995) (0)
- Exploration des facteurs biologiques prédictifs de la progression après chirurgie dans le carcinome rénal à haut risque : résultats de la cohorte française des patients de l’essai randomisé S-TRAC (2020) (0)
- Stratégie de prise en charge des cancers de la prostate réfractaires à la castration (2012) (0)
- Traitement adjuvant du cancer du rein (2011) (0)
- Intérêt du traitement adjuvant par antiangiogénique versus surveillance après néphrectomie pour tumeur rénale M0 avec thrombus de la veine rénale ou de la veine cave (étude UroCCR-56) (2019) (0)
- Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Exploratory pharmacogenomic analysis. (2018) (0)
- Strategical and decisional trees (2002) (0)
- Infection SARS-CoV-2/COVID 19et cancers solides: synthse des recommandations l'attention des professionnels de sant./ [SARS-CoV-2/COVID 19Infection and Solid Cancers: Synthesis of Recommendations for Health Professionals]. (2020) (0)
- Curage rétropéritonéal robot-assisté de masses résiduelles de tumeur germinale non séminomateuse (TGNS) avec thrombectomie cave (2021) (0)
- Quelle place pour les stratégies médicales adjuvante et néoadjuvante en phase localisée (2008) (0)
- Plate-forme de pharmacoépidémiologie en cancérologie (2009) (0)
- Parcours de soins en cancérologie et financement (2014) (0)
- Hilar Fat Infiltration: An Independent Prognostic Factor in Metastatic Clear Cell Renal Cell Carcinoma with Sunitinib First-Line Treatment (2017) (0)
- Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option? (2023) (0)
- Nomogram Predicting Prognosis in Metastatic Patients with Clear Cell Renal Cell Carcinoma Treated by First-Line Sunitinib (2017) (0)
- 7157 Subgroup analysis of French patients from RECORD-1: a randomized, placebo-controlled, phase III study of everolimus, a novel therapy for patients with metastatic renal cell carcinoma (2009) (0)
- The experimental renal cell carcinoma model in the chick embryo (2012) (0)
- Systemic adjuvant chemotherapy for soft tissue sarcomas (1997) (0)
- Trial on progress: VOTRAGE study Phase I study with geriatric criteria of Pazopanib in a population of frail elderly patients after geriatric assessment (2013) (0)
- 265 Phase 1b study of avelumab + M9241 (NHS-IL12) in patients with advanced solid tumors: interim analysis results from a urothelial carcinoma (UC) dose-expansion cohort (2020) (0)
- S-TRAC trial: Sensitivity analyses of disease-free survival (DFS). (2018) (0)
- R131 Chirurgie des métastases après traitement en première ligne du cancer colorectal par bévacizumab : résultats de la cohorte ETNA (2010) (0)
- 1314P Preliminary results of sequential combination of immunotherapy followed by chemotherapy in advanced non-small cell lung cancer (2021) (0)
- [Management of side effects of targeted therapies in renal cancer: iatrogenic side effects]. (2011) (0)
- [Strategy in advanced castration-resistant prostate cancer]. (2012) (0)
- 1400 POSTER DISCUSSION Interest of CHOI and Modified CHOI Criterion for Evaluation of Metastatic Renal Cell Carcinomas (mRCC) Patients Treated With Everolimus (2011) (0)
- Schémas de prescription alternatif du sunitinib dans le cancer du rein métastatique: de l’underground au grand public? (2014) (0)
- Évaluation de la tomographie par émission de positons à la 18Fluorocholine (FCH-TEP) dans le bilan initial du cancer de la prostate (CP) à haut risque et à risque intermédiaire : étude prospective sur 97 patients (2013) (0)
- Soft tissue sarcoma (STS) of the extremities. Conservative treatment by surgery and post-operative radiotherapy (1993) (0)
- Prostate-Specific Antigen Doubling Time: A Potential Surrogate End Point in Hormone-Refractory Prostate Cancer (1998) (0)
- Array-comparative genomic hybridization to predict resistance to VEGF-targeted therapies in patients with metastatic clear cell renal cell carcinoma. (2016) (0)
- The development of a regional referral pathway for locally recurrent rectal cancer: A Delphi consensus study. (2019) (0)
- OP0088 Immune-related adverse events of cancer immunotherapy – when inflammatory side effects are associated with survival: a single-centre prospective cohort study (2018) (0)
- [Bladder cancer and new drugs]. (2010) (0)
- MP25-17 NEUTROPHIL- AND PLATELET-TO-LYMPHOCYTE RATIOS AS PROGNOSTIC FACTORS OF DISEASE-FREE SURVIVAL IN HIGH-RISK RENAL CELL CARCINOMA (2019) (0)
- S-TRAC adjuvant sunitinib phase 3 trial in patients with high risk renal cell carcinoma: Subgroups analyses by risk factors (2017) (0)
- SAT0540 ONE-YEAR OUTCOMES AFTER RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS FROM CHECKPOINT INHIBITORS (2020) (0)
- [Treatment of cancer of the kidney with interleukin 2 in adults, the Lyon experience]. (1992) (0)
- What is new in renal cell carcinoma (2002) (0)
- Étude de phase II étudiant la capacité de l’axitinib à transformer les tumeurs du rein cT2a en cT1 et permettre une néphrectomie partielle (AXIPAN) (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Alain Ravaud?
Alain Ravaud is affiliated with the following schools:
